The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effects of gene expression in 5-FU metabolic pathways in a phase III trial evaluating adjuvant S-1 therapy compared to surgery alone following curative resection for biliary tract cancer (JCOG1202A1).
 
Shuichi Mitsunaga
Speakers' Bureau - Ono Pharmaceutical; Otsuka
Research Funding - Astellas Pharma; Chugai Pharma; Ono Pharmaceutical; PFDeNA; Toray Industries
 
Masafumi Ikeda
Honoraria - Abbott Laboratories; Abbvie; AstraZeneca; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; EA Pharma; Eisai; Fujifilm; Incyte; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Taisho Pharmaceutical Holdings; Takeda; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Eisai; EMD Serono; GlaxoSmithKline; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; SERVIER; Takeda
Research Funding - AstraZeneca (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); InVitae (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nihon Servier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Syneos Health (Inst)
 
Shogo Nomura
Employment - Asahi Kasei (I)
Honoraria - AstraZeneca; Chugai Pharma; Kyowa Hakko Bio
Research Funding - Amgen Astellas BioPharma (Inst); AstraZeneca (Inst)
 
Chigusa Morizane
Honoraria - Eisai; MSD K.K.; Novartis; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - MSD K.K.; SERVIER; Yakult Honsha
Research Funding - AstraZeneca (Inst); Daiichi Sankyo RD Novare; Eisai (Inst); Hitachi (Inst); J-Pharma (Inst); Merck (Inst); ONO PHARMACEUTICAL (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Akiko Todaka
Honoraria - Nihon Servier; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
 
Keiko Kamei
No Relationships to Disclose
 
Hiroo Yanagibashi
No Relationships to Disclose
 
Nobumasa Mizuno
Honoraria - AstraZeneca; Fujifilm; Novartis; Yakult Honsha
Consulting or Advisory Role - AstraZeneca
Research Funding - ASLAN Pharmaceuticals (Inst); Incyte (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Seagen (Inst); Yakult Honsha (Inst)
 
Kunihito Gotoh
Research Funding - Eisai
 
Yasuyuki Kawamoto
Honoraria - Incyte; Lilly; Merck; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Japan Agency for Medical Research and Development; Takeda
 
Hirofumi Shirakawa
No Relationships to Disclose
 
Naohiro Okano
Honoraria - Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - GlaxoSmithKline
 
Tatsuya Nomura
No Relationships to Disclose
 
Amane Takahashi
No Relationships to Disclose
 
Isamu Makino
No Relationships to Disclose
 
Yoshiyasu Anbo
No Relationships to Disclose
 
Koji Ohta
No Relationships to Disclose
 
Hiroshi Katayama
No Relationships to Disclose
 
Masaru Konishi
No Relationships to Disclose
 
Makoto Ueno
Honoraria - AstraZeneca; Chugai Pharma; Incyte; MSD; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Novocure
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); Incyte (Inst); JPH Clinical Development (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)